Gary J. Kelloff

National Institutes of Health
United States

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 92 Citations 32,854 317 World Ranking 6983 National Ranking 3762

Overview

What are the main themes of his work throughout his whole career to date

Gary J. Kelloff connects Colorectal cancer with Cancer prevention in his study. Gary J. Kelloff performs multidisciplinary study in Cancer prevention and Colorectal cancer in his work. His research on Pathology frequently connects to adjacent areas such as Micronutrient. His Pathology research extends to Micronutrient, which is thematically connected. In his papers, Gary J. Kelloff integrates diverse fields, such as Cancer and Oncology. In his papers, Gary J. Kelloff integrates diverse fields, such as Oncology and Cancer. Internal medicine is closely attributed to Aspirin in his work. His work on Internal medicine expands to the thematically related Aspirin. Aberrant crypt foci is often connected to Colonic disease in his work.

Gary J. Kelloff most often published in these fields:

Colorectal cancer (100.00%)
Pathology (100.00%)
Cancer (100.00%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis

Gideon Steinbach;Patrick M. Lynch;Robin K S Phillips;Marina H. Wallace.
The New England Journal of Medicine (2000)

3119 Citations

Chemopreventive Effect of Curcumin, a Naturally Occurring Anti-Inflammatory Agent, during the Promotion/Progression Stages of Colon Cancer

Toshihiko Kawamori;Ronald Lubet;Vernon E. Steele;Gary J. Kelloff.
Cancer Research (1999)

851 Citations

Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

Gary J. Kelloff;John M. Hoffman;Bruce Johnson;Howard I. Scher.
Clinical Cancer Research (2005)

760 Citations

The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.

Russell F. Jacoby;Karen Seibert;Carolyn E. Cole;Gary Kelloff.
Cancer Research (2000)

704 Citations

I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

AD Barker;CC Sigman;GJ Kelloff;NM Hylton.
Clinical Pharmacology & Therapeutics (2009)

697 Citations

Chemoprevention of Colon Cancer by Specific Cyclooxygenase-2 Inhibitor, Celecoxib, Administered during Different Stages of Carcinogenesis

Bandaru S. Reddy;Yoshinobu Hirose;Ronald Lubet;Vernon Steele.
Cancer Research (2000)

634 Citations

Progress in Cancer chemoprevention : Development of diet-derived chemopreventive agents

Gary J. Kelloff;James A. Crowell;Vernon E. Steele;Ronald A. Lubet.
Journal of Nutrition (2000)

595 Citations

Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review.

Charles W. Boone;Gary J. Kelloff;Winfred E. Malone.
Cancer Research (1990)

590 Citations

Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia

Joyce A. O’Shaughnessy;Gary J. Kelloff;Gary B. Gordon;Andrew J. Dannenberg.
Clinical Cancer Research (2002)

520 Citations

Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent.

Chinthalapally V. Rao;Abraham Rivenson;Barbara Simi;Edith Zang.
Cancer Research (1995)

518 Citations

If you think any of the details on this page are incorrect, let us know.